ATE145669T1 - T-pa substitutionsvarianten mit verbesserter fibrinspezifität - Google Patents

T-pa substitutionsvarianten mit verbesserter fibrinspezifität

Info

Publication number: ATE145669T1
Authority: AT; Austria
Prior art keywords: variants; prepared; expression vectors; dna sequences; substitution variants
Prior art date: 1991-12-16

Application number

AT93901234T

Other languages

English (en)

Inventor

William F Bennett

Bruce A Keyt

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-16

Filing date

1992-12-14

Publication date

1996-12-15

1992-12-14 Application filed by Genentech Inc filed Critical Genentech Inc

1996-12-15 Application granted granted Critical

1996-12-15 Publication of ATE145669T1 publication Critical patent/ATE145669T1/de

Links

102000009123 Fibrin Human genes 0.000 title abstract 2
108010073385 Fibrin Proteins 0.000 title abstract 2
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 title abstract 2
229950003499 fibrin Drugs 0.000 title abstract 2
238000006467 substitution reaction Methods 0.000 title abstract 2
108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 abstract 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 abstract 2
239000013604 expression vector Substances 0.000 abstract 2
229960000187 tissue plasminogen activator Drugs 0.000 abstract 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract 1
239000004475 Arginine Substances 0.000 abstract 1
101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 abstract 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
239000004473 Threonine Substances 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000008021 deposition Effects 0.000 abstract 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
102000047823 human PLAT Human genes 0.000 abstract 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
229960000310 isoleucine Drugs 0.000 abstract 1
125000001909 leucine group Chemical class [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
208000019553 vascular disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biotechnology (AREA)
Diabetes (AREA)
Hematology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)

AT93901234T 1991-12-16 1992-12-14 T-pa substitutionsvarianten mit verbesserter fibrinspezifität ATE145669T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US80812191A	1991-12-16	1991-12-16

Publications (1)

Publication Number	Publication Date
ATE145669T1 true ATE145669T1 (de)	1996-12-15

Family

ID=25197925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93901234T ATE145669T1 (de)	1991-12-16	1992-12-14	T-pa substitutionsvarianten mit verbesserter fibrinspezifität

Country Status (8)

Country	Link
EP (1)	EP0618973B1 (de)
JP (1)	JP3696617B2 (de)
AT (1)	ATE145669T1 (de)
AU (1)	AU665979B2 (de)
CA (1)	CA2124937C (de)
DE (1)	DE69215537T2 (de)
NZ (1)	NZ246467A (de)
WO (1)	WO1993012238A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993012225A1 (en) *	1991-12-16	1993-06-24	Genentech, Inc.	Novel tissue plasminogen activator variants
DE10153601A1 (de)	2001-11-02	2003-05-22	Paion Gmbh	DSPA zur Behandlung von Schlaganfall
DE10342518A1 (de) *	2003-09-12	2005-05-12	Paion Gmbh	Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU206520B (en) *	1985-04-22	1992-11-30	Genentech Inc	Process for producing new human tissue plasminogen activator /tpa/ mutants and pharmaceutical compositions containing them
DK275788A (da) *	1987-05-22	1989-02-03	Zymogenetics Inc	Fibrinolytiske proteiner

1992
- 1992-12-14 CA CA002124937A patent/CA2124937C/en not_active Expired - Lifetime
- 1992-12-14 EP EP93901234A patent/EP0618973B1/de not_active Expired - Lifetime
- 1992-12-14 DE DE69215537T patent/DE69215537T2/de not_active Expired - Lifetime
- 1992-12-14 WO PCT/US1992/010902 patent/WO1993012238A1/en not_active Ceased
- 1992-12-14 AU AU33242/93A patent/AU665979B2/en not_active Expired
- 1992-12-14 AT AT93901234T patent/ATE145669T1/de active
- 1992-12-14 NZ NZ246467A patent/NZ246467A/en unknown
- 1992-12-14 JP JP51116893A patent/JP3696617B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0618973A1 (de)	1994-10-12
JP3696617B2 (ja)	2005-09-21
JPH07501946A (ja)	1995-03-02
CA2124937C (en)	2001-06-05
DE69215537T2 (de)	1997-04-30
AU3324293A (en)	1993-07-19
NZ246467A (en)	1995-10-26
WO1993012238A1 (en)	1993-06-24
CA2124937A1 (en)	1993-06-24
EP0618973B1 (de)	1996-11-27
DE69215537D1 (de)	1997-01-09
AU665979B2 (en)	1996-01-25

Similar Documents

Publication	Publication Date	Title
Shimokawa et al.	1997	Sequence and Biological Activity of Catrocollastatin-C: A Disintegrin-Like/Cysteine-Rich Two-Domain Protein fromCrotalus atroxVenom
IL91306A (en)	1997-08-14	Tissue plasminogen variant having amino acid substitution in the protease domain having improved zymogenic or fibrin specific properties
HU218831B (hu)	2000-12-28	Eljárás megnövelt hatású, katalitikus helyre irányuló trombin inhibitorok és ezeket tartalmazó gyógyszer-, és diagnosztikai készítmények előállítására
JPH05500750A (ja)	1993-02-18	血小板凝集阻害剤
US5066592A (en)	1991-11-19	Trigramin - a platelet aggregation inhibiting polypeptide
US5491129A (en)	1996-02-13	Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
WO2002048180A3 (de)	2003-01-30	Peptide und/oder proteine sowie verwendung desselben zur herstellung eines therapeutischen und/oder präventiven arzneimittels
ATE145669T1 (de)	1996-12-15	T-pa substitutionsvarianten mit verbesserter fibrinspezifität
Davis III et al.	1979	Human factor. hivin. D of the alternative complement pathway. Physicochemical characteristics and N-terminal amino acid sequence
EP0330700A4 (de)	1990-01-08	Menschlicher Prourokinase ähnliches Polypeptid.
Collen et al.	1975	Human plasminogen: in vitro and in vivo evidence for the biological integrity of NH2-terminal glutamic acid plasminogen
DE69105121D1 (de)	1994-12-15	Gewebeplasminogenaktivator mit fibrin-spezifischen eigenschaften.
Weinstein et al.	1990	Enhancement of rabbit protein S anticoagulant cofactor activity in vivo by modulation of the protein S C4B binding protein interaction.
JPH06217773A (ja)	1994-08-09	フィブリン親和性ウロキナーゼ複合体とその製法
DE69113049D1 (de)	1995-10-19	Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
EP0942996A1 (de)	1999-09-22	Thrombolytische substanzen mit antithrombotische aktivität
Cierniewski et al.	1993	Localization of the cross‐linking site of GPRVVERHK in the γ‐chain of human fibrinogen
Aronson et al.	1980	Human prothrombin fragments FI (αβ) and F2: Preparation and characterization of structural and biological properties
DE69105213D1 (de)	1994-12-22	Substitutionsvariante des gewebeplasminogenaktivators.
Murakami et al.	1989	A cytocidal tissue kallikrein isolated from mouse submandibular glands
JPH0618782B2 (ja)	1994-03-16	組織プラスミノーゲン活性化因子製剤
Miyagi et al.	1998	Purification of haemorrhagic proteinase from the venom of Agkistrodon caliginosus (Kankoku-Mamushi)
EP0326013A3 (de)	1990-08-22	Von menschlichem alpha-2-Plasmin-Inhibitor abgeleitete neue Proteine oder Proteine, die diesen ähnlich sind
MIRZA	1990	jllafiter of $ l\| ilofl (oplip

Legal Events

Date	Code	Title	Description
1997-06-15	UEP	Publication of translation of european patent specification